Sponsored By

Podcast: Biopharma’s evolving relationships with CDMOs

Dan Stanton

May 4, 2022

M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics.

The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolving relationships between biopharma and their contract development and manufacturing organization (CDMO) partners.

CDMO-panel-300x180.jpg

Recorded live from EBD’s BIO Europe Spring event last month, BioProcess Insider discussed the changing dynamic and reliance drug sponsors have with their CDMOs with:

  • Kevin Sharp, VP, Head of Global Sales Strategic Operations, Samsung Biologics

  • Barbara Sambuco, VP Operations, Drug Product, Biotherapeutics, Catalent

  • Christoph Winterhalter, SVP, Business Development, AGC Biologics

You can listen to the full panel via Spotify, Apple iTunes, Google Podcasts, and other platforms, or listen directly below:

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.